Supplementation of EPA prevented platelet aggregation in response to various agonists [26], reduced the coagulation factors prothrombin and factor V [10] as well as thrombin generation [27], diminished endothelial dysfunction as assessed by flow-mediated dilatation [14], and decreased inflammatory markers including platelet-derived soluble CD40 ligand [28]. This evidence concerns the gene F2 and endothelial dysfunction.